Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–62.

Article  CAS  PubMed  Google Scholar 

Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571–84.

Article  PubMed  Google Scholar 

Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet. 2024;403:1177–91.

Article  CAS  PubMed  Google Scholar 

Nielsen OH, Fernandez-Banares F, Sato T, et al. Microscopic colitis: Etiopathology, diagnosis, and rational management. Elife. 2022;11:e79397.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.

Article  PubMed  Google Scholar 

Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165:1197–205.

Article  CAS  PubMed  Google Scholar 

Kornbluth A. Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998;4:328–9.

Article  CAS  PubMed  Google Scholar 

Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.

Article  CAS  PubMed  Google Scholar 

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

Article  CAS  PubMed  Google Scholar 

Lang L. The food and drug administration approves humira. Gastroenterology. 2007;132:1644–5.

Google Scholar 

Savelkoul EHJ, Thomas PWA, Derikx L, et al. Systematic review and meta-analysis: Loss of response and need for dose escalation of infliximab and adalimumab in ulcerative colitis. Inflamm Bowel Dis. 2023;29:1633–47.

Article  PubMed  Google Scholar 

Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35:715–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brun MK, Gehin JE, Bjorlykke KH, et al. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials. Lancet Rheumatol. 2024;6:e226–36.

Article  CAS  PubMed  Google Scholar 

Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341–53.

Article  PubMed  Google Scholar 

Khanna R, Vande CN. Use of precision medicine in clinical trials in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:213–6.

Article  PubMed  Google Scholar 

Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5:454–64.

Article  PubMed  Google Scholar 

Vallejo-Yague E, Keystone EC, Kandhasamy S, et al. Primary and secondary non-response: in need of operational definitions in observational studies. Ann Rheum Dis. 2021;80:961–4.

Article  PubMed  Google Scholar 

Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2020;14:542–56.

Article  PubMed  Google Scholar 

Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: Definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anjie SI, Hulshoff MS, D’Haens G. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand? Expert Opin Biol Ther. 2023;23:341–51.

Article  CAS  PubMed  Google Scholar 

Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNF-alpha dose intensification in Crohn’s disease. J Gastroenterol. 2017;52:535–54.

Article  CAS  PubMed  Google Scholar 

Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:838–46.

Article  CAS  PubMed  Google Scholar 

Yang H, Li B, Guo Q, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55:764–77.

Article  CAS  PubMed  Google Scholar 

Fousekis FS, Papamichael K, Kourtis G, et al. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann Gastroenterol. 2022;35:1–7.

PubMed  Google Scholar 

Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–27.

Article  PubMed  Google Scholar 

Wu JF. Therapeutic drug monitoring of biologics for patients with inflammatory bowel diseases: How, when, and for whom? Gut Liver. 2022;16:515–24.

Article  CAS  PubMed  Google Scholar 

Schultheiss JPD, Mahmoud R, Louwers JM, et al. Loss of response to anti-TNF-alpha agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54:1298–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol. 2008;103:944–8.

Article  CAS  PubMed  Google Scholar 

Ben-Horin S, Heap GA, Ahmad T, et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol. 2015;9 (Suppl 1):27–34.

Article  PubMed  Google Scholar 

Bar-Yoseph H, Pressman S, Blatt A, et al. Infliximab-tumor necrosis factor complexes elicit formation of anti-drug antibodies. Gastroenterology. 2019;157:1338–51.

Article  CAS  PubMed  Google Scholar 

Marsal J, Barreiro-de Acosta M, Blumenstein I, et al. Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Front Med (Lausanne). 2022;9: 897936.

Article  PubMed  PubMed Central  Google Scholar 

Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–34.

Article  PubMed  Google Scholar 

Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171–85.

Article  CAS